Open AccessCamrelizumab combined with microwave ablation improves the objective response rate in advanced non-small cell lung cancer
Author(s) -
Zhigang Wei,
Xia Yang,
Xin Ye,
Guanghui Huang,
Wenhong Li,
Xiaoying Han,
Jiao Wang,
Min Meng,
Yang Ni,
Zhigeng Zou,
Qiang Wen
Publication year - 2019
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_990_19
Subject(s) - medicine , microwave ablation , adverse effect , lung cancer , clinical endpoint , surgery , neutropenia , leukopenia , progression free survival , oncology , gastroenterology , chemotherapy , randomized controlled trial , ablation
The present study evaluated the safety and efficacy of camrelizumab (a programmed death-1 antibody) in combination with microwave ablation (MWA) in advanced non-small cell lung cancer (NSCLC).